Additional file 1 of Treatment with recombinant Sirt1 rewires the cardiac lipidome and rescues diabetes-related metabolic cardiomyopathy
Creators: name: Costantino, Sarah
name: Mengozzi, Alessandro
name: Velagapudi, Srividya
name: Mohammed, Shafeeq Ahmed
name: Gorica, Era
name: Akhmedov, Alexander
name: Mongelli, Alessia
name: Pugliese, Nicola Riccardo
name: Masi, Stefano
name: Virdis, Agostino
name: Hülsmeier, Andreas
name: Matter, Christian Matthias
name: Hornemann, Thorsten
name: Melina, Giovanni
name: Ruschitzka, Frank
name: Luscher, Thomas Felix
name: Paneni, Francesco
Publisher: name: figshare
Year: 2024
Subjects: subject: Biochemistry
subject: Medicine
subject: Cell Biology
subject: Genetics
subject: FOS: Biological sciences
subject: Molecular Biology
subject: Physiology
subject: Pharmacology
subject: Chemical Sciences not elsewhere classified
subject: Cancer
subject: Computational Biology

description: Additional file1: Figure S1. Schematic study protocol. At 12 weeks, db/db mice were administered recombinant Sirt1 (rSirt1) by intraperitoneal injection, 0.3 mg/Kg every other day. At 16 weeks, mice cardiac function and structure were evaluated, and then mice were sacrificed and harvested for molecular analyses. rSirt1 recombinant Sirt1. Figure S2. rSirt1 treatment effect on cardiac geometry and physiology. A Left ventricular end-diastolic and end-systolic internal diameters, volumes and mass of the three experimental groups: db/+ mice (black dots and plots; n=11); db/db mice (red dots and plots; n=12); db/db mice after 4-week treatment with rSirt1 (green dots and plots; n=13). B Stroke volume, heart rate and cardiac output of the three experimental groups. Data are presented as violin plots showing median [IQR] and compared by the Kruskal-Wallis test (upper bold bar) with Dunn post hoc test. *p&lt;0.05, **p&lt;0.01. EDV end-diastolic volume, ESV end-systolic volume, LVIDd left ventricular end-diastolic internal diameter, LVIDs left ventricular end-systolic internal diameter; rSirt1: recombinant Sirt1. Table S1. Cardiac lipidomics analysis performed in the three experimental groups (n=6 for each group). Data are presented as median [IQR] and compared by the Kruskal-Wallis test and corrected for multiple testing by the two stage step-up Benjamini, Krieger and Yekutieli false discovery rate method at an alpha level of 0.05. TAG triacylglycerol. Table S2. Expression level data of genes involved in lipid metabolism, trafficking and inflammation in the three experimental groups (n=4 for each group). Data are presented as mean±SD and compared by the two-way ANOVA and corrected for multiple testing by the two stage step-up Benjamini, Krieger and Yekutieli false discovery rate method at an alpha level of 0.05. Acox3 Acyl-CoA Oxidase 3, Acsl1 Acyl-CoA Synthetase Long Chain Family Member 1, Apoa5 Apolipoprotein A5, Apoc3 Apolipoprotein C3, Cd36 Cluster of differentiation 36, Cpt1a Carnitine Palmitoyltransferase 1A, Cpt1b Carnitine Palmitoyltransferase 1B, Fabp1 Fatty Acid Binding Protein 1, Fabp2 Fatty Acid Binding Protein 2, Fads2 Fatty Acid Desaturase 2, Lpl Lipoprotein Lipase, Mmp9 Matrix Metallopeptidase 9, Ncoa3 Nuclear Receptor Coactivator 3, Ppara Peroxisome Proliferator Activated Receptor Alpha, Ppard Peroxisome Proliferator Activated Receptor Delta, Pparg Peroxisome Proliferator Activated Receptor Gamma, Pten Phosphatase And Tensin Homolog, Plin3 Perilipin 3. Table S3. Expression level data of genes involved in lipid metabolism, trafficking and inflammation in the four experimental groups of the in vitro experiments (n=5 for each group). Data are presented as mean±SD and compared by the two-way ANOVA and corrected for multiple testing by the two stage step-up Benjamini, Krieger and Yekutieli false discovery rate method at an alpha level of 0.05. Cd36 Cluster of differentiation 36, Il1b Interleukin-1β, Il6 Interleukin-6, Lpl Lipoprotein Lipase, Ppara Peroxisome Proliferator Activated Receptor Alpha, Pparg Peroxisome Proliferator Activated Receptor Gamma, Plin3 Perilipin 3, Tnfa Tumour Necrosis Factor-α. Table S4. Anthropometric, clinical and biochemical characteristics of the study population. Data are presented as median [IQR] and compared by the Mann-Whitney U test and the Fischer’s exact test for categorical variables. ACE-i: angiotensin-converting enzyme inhibitors ARBs angiotensin receptor blockers, BMI body mass index, EF ejection fraction, FS fractional shortening HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, LVEDD left ventricular end-diastolic diameter, LVESD left ventricular end-systolic diameter, LVM: left ventricular mass, T2D type 2 diabetes.